STOCK TITAN

Madrigal Pharmac - MDGL STOCK NEWS

Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.

Madrigal Pharmaceuticals, Inc. (MDGL) is a clinical-stage biopharmaceutical company pioneering treatments for metabolic dysfunction-associated steatohepatitis (MASH), including its FDA-approved therapy Rezdiffra. This page provides investors and healthcare professionals with timely updates on corporate milestones, clinical research, and regulatory developments.

Access the latest press releases, earnings reports, and scientific announcements in one centralized location. Key updates include Rezdiffra's commercialization progress, new clinical data analyses, and strategic partnerships advancing MASH treatment innovation. Our curated news collection ensures you stay informed about material events without speculative commentary.

Regular updates cover regulatory submissions, trial expansions, financial disclosures, and patient access initiatives. Content is rigorously verified to provide accurate, actionable information for investment and therapeutic decision-making. Bookmark this page to monitor Madrigal's progress in addressing critical unmet needs in liver disease therapeutics.

Rhea-AI Summary

Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced the release date for its second-quarter 2024 financial results. The company will disclose the results on Wednesday, August 7, 2024, before the U.S. financial markets open. Following this, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to review the financial and operating results.

Investors and interested parties can access the webcast through the Investor Relations section of Madrigal Pharmaceuticals' website. To ensure a smooth connection, participants are advised to register at least 15 minutes before the scheduled start. The webcast will remain available for approximately two hours after the live event concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
-
Rhea-AI Summary

Madrigal Pharmaceuticals announced new data from the Phase 3 MAESTRO-NASH study of Rezdiffra™ (resmetirom) at the EASL Congress.

The study showed Rezdiffra improved key fibrotic features predictive of cirrhosis. AI-driven analysis revealed that 80% of patients treated with Rezdiffra experienced fibrosis improvement or stabilization. In noninvasive tests over three years, 91% showed improved or stable liver stiffness.

Health-related quality of life metrics also improved, including reductions in worry, health distress, and stigma. Additionally, Rezdiffra had positive outcomes in patients with Metabolic Dysfunction and Alcohol-Associated Liver Disease (MetALD).

The data supports Rezdiffra as a foundational therapy in NASH, demonstrating durable responses and broad treatment benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
-
Rhea-AI Summary

Madrigal Pharmaceuticals (Nasdaq: MDGL) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. The company will present at 8:40 A.M. ET, with the presentation webcast live on Madrigal’s Investor Relations Events page. A replay of the webcast will be available post-event. This participation reflects Madrigal's engagement with key industry stakeholders and potential investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
conferences
Rhea-AI Summary

Madrigal Pharmaceuticals, a biopharma company specializing in NASH treatment, will present ten data abstracts at the EASL Congress from June 5-8, 2024, in Milan.

The presentations will focus on Rezdiffra™ (resmetirom), a novel THR-β agonist and the first approved NASH therapy. Highlights include new Phase 3 MAESTRO data on quality of life, noninvasive test results, and Rezdiffra's efficacy in MetALD patients.

Additionally, Madrigal will showcase real-world data on NASH's human and economic impact, noting faster progression to severe liver conditions than previously thought.

Rezdiffra has shown significant efficacy in improving or stabilizing fibrosis in 80% of patients and is indicated for noncirrhotic NASH with moderate to advanced fibrosis. Continued approval hinges on ongoing confirmatory trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
conferences
-
Rhea-AI Summary

Madrigal Pharmaceuticals reported strong financial results for the first quarter of 2024, highlighted by the approval and launch of Rezdiffra™ for the treatment of NASH. The company raised $690 million in gross proceeds from a public offering, with cash, cash equivalents, and marketable securities totaling $1.1 billion as of March 31, 2024. Key corporate updates include the appointment of a new CFO and the validation of the European Medicines Agency marketing application for resmetirom.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
-
Rhea-AI Summary
Madrigal expresses deep sorrow over the passing of Dr. Stephen Harrison, a pivotal figure in NASH research. Dr. Harrison's dedication to improving the lives of NASH patients and his collaborative approach with various stakeholders leaves a lasting impact on the field of hepatology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
none
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) will release its first-quarter 2024 financial results on May 7, 2024. The management will host a live webcast to review the financial and operating results at 8 a.m. Eastern Time. Participants can access the webcast on the company's Investor Relations section of the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.29%
Tags
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. granted equity awards to 7 new employees under Nasdaq Listing Rule 5635(c)(4), with options to purchase 1,979 shares of common stock and 4,078 time-based restricted stock units. The options have an exercise price of $231.37 per share and vest over time, while the restricted stock units vest in increments over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
none
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. announces FDA approval of Rezdiffra for NASH treatment, marking a significant milestone in the NASH community. Rezdiffra is now available in the U.S. for adults with noncirrhotic NASH with moderate to advanced liver fibrosis. The medication does not require a biopsy for diagnosis, a patient-centric approach applauded by healthcare advocates. The first patients have started receiving Rezdiffra, showcasing a pivotal moment for Madrigal and NASH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (MDGL) granted equity awards to 30 new employees under its 2023 Inducement Plan. The awards include options to purchase 1,813 shares and 12,709 restricted stock units. The options have an exercise price of $255.74 per share and vest over time. The restricted stock units vest in increments over four years, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
Madrigal Pharmac

Nasdaq:MDGL

MDGL Rankings

MDGL Stock Data

6.66B
20.13M
8.74%
105.1%
17%
Biotechnology
Pharmaceutical Preparations
Link
United States
WEST CONSHOHOCKEN